リケラボ論文検索は、全国の大学リポジトリにある学位論文・教授論文を一括検索できる論文検索サービスです。

リケラボ 全国の大学リポジトリにある学位論文・教授論文を一括検索するならリケラボ論文検索大学・研究所にある論文を検索できる

リケラボ 全国の大学リポジトリにある学位論文・教授論文を一括検索するならリケラボ論文検索大学・研究所にある論文を検索できる

大学・研究所にある論文を検索できる 「New insights into patterns of first metastatic sites influencing survival of patients with hormone receptor-positive, HER2-negative breast cancer: a multicenter study of 271 patients」の論文概要。リケラボ論文検索は、全国の大学リポジトリにある学位論文・教授論文を一括検索できる論文検索サービスです。
リケラボ

コピーが完了しました

URLをコピーしました

論文の公開元へ論文の公開元へ
書き出し

New insights into patterns of first metastatic sites influencing survival of patients with hormone receptor-positive, HER2-negative breast cancer: a multicenter study of 271 patients

山村 順 近畿大学

2022.12.08

概要

Background: The initial therapeutic strategy for hormone receptor-positive (HR+), HER2-negative (HER2-) breast cancer is based on the first metastatic site; however, little evidence is available regarding the influence of metastatic distribution patterns of first metastatic sites on prognosis. In this study, we aimed to identify the metastatic distribution patterns of first metastatic sites that significantly correlate with survival after recurrence.

Methods: We performed a retrospective review of records from 271 patients with recurrent metastatic HR+/HER2- breast cancer diagnosed between January 2000 and December 2015. We assessed survival after recurrence according to the metastatic distribution patterns of the first metastatic sites and identified significant prognostic factors among patients with single and multiple metastases.

Results: Prognosis was significantly better in patients with a single metastasis than in those with multiple metastases (median overall survival after recurrence: 5.86 years vs. 2.50 years, respectively, p < 0.001). No metastatic organ site with single metastasis was significantly associated with prognostic outcome, although single metastasis with diffuse lesions was an independent risk factor for worse prognosis (HR: 3.641; 95% Cl: 1.856-7.141) and more easily progressing to multiple metastases {p- 0.002). Multiple metastases, including liver metastasis (HR: 3.145; 95% Cl: 1.802-5.495) or brain metastasis (HR: 3.289; 95% Cl: 1.355-7.937), were regarded as significant independent poor prognostic factors; however, multiple metastases not involving liver or brain metastasis were not significantly related to prognosis after recurrence.

Conclusions: Single metastases with diffuse lesions could more easily disseminate systemically and progress to multiple metastases, leading to a poor prognosis similar to multiple metastases. Our findings indicate that the reconsideration of the determinant factors of therapeutic strategies for first recurrence in HR+/HER2- breast cancer may be needed.

論文の公開元へ

関連論文

関連論文をもっと見る

参考文献

1. National Cancer Institute Surveillance, Epidemiology, and End Results Program. Cancer statistics: Cancer Stat Facts: Female Breast Cancer. National Cancer Institute; 2019. httpy/seer.cancer.gov/statfacts/html/breast.html. Accessed 2 Oct 2019

2. Hortobagyi GN. de la Garza SJ, Pritchard K Amadori D, Haidinger R, Hudis CA et al. The global breast cancer burden: variations in epidemiology and survival. Clin Breast Cancer. 2005,6(5)391 401. https://doi.Org/1038l6/CBC.2 005.n.043.

3. Giuliani J, Bonetti A. Trends in survival for patients with metastatic breast cancer: is survival improving. Tumori. 2015:101(4)347-52. https://doi.ocg/10. 5301/tj.500030l.

4. Chung CT, Carlson RW. Goals and objectives in the management of metastatic breast cancer. Oncologist. 2003;8(6):514-20. https//doi.org/10.1 634/theoncologist8-6-514.

5. Harb WA. Management of patients with hormone receptor-positive breast cancer with visceral disease: challenges and treatment options. Cancer Manag Res. 2015;7:37-46. http$y/doiorg/l0.2147/CMAR.S72592.

6. Lobbezoo DJ. van Kampen RJ, Voogd AG Dercksen MW, van den Berkmortel F, Smilde TJ, et al. Prognosis of metastatic breast cancer subtypes: the hormone receptor/HER2-positive subtype is associated with the most favorable outcome. Breast Cancer Res Treat 2013; 141 (3):5O7 14. https://doi.Org/10.1007/s10549-013-2711 -y.

7. National Comprehensive Cancer Network. NCCN clinical practice guidelines in oncology (NCCN guidelines*) with NCCN evidence blocks'" 2019. https// www.nccn.org/EvidenceBlocks/. Accessed 8 Oct 2019.

8. Schnipper L, Davidson N, Wollins D, Blayney DW, Dicker AP, Ganz PA, et al. Updating the American Society of Clinical Oncology value framework revisions and reflections in response to comments received. J Gin Oncol. 2016;34(24):2925 34. https//doi.org/10.1200/JC02016.682518.

9. Cardoso F. Senkus E, Costa A Papadopoulos E. Aapro M, Andr^ F. et al. 4th ESO-ESMO international consensus guidelines for advanced breast cancer (ABC 4). Ann Oncol. 2018;29(8):l634-57. https//doi.org/l0.1093/annonc/ mdy192.

10. Le Saux 0. Lardy-Cleaud A. Frank S, Debled M, Cottu PH. Pistilli B. et al. Assessment of the efficacy of successive endocrine therapies in hormone receptor-positive and HER2-negative metastatic breast cancer a real-life multicentre national study. Eur J Cancer. 2019;!18:131 41. https//doi.org/l 0.1016/).ejca2019.06.014.

11. Yamamura J. Kamigaki 5, Tsujie M, Fujita J, Osato H, Higashi G et al. Response to first-line recurrence treatment influences survival in hormone receptor-positive, HER2-negative breast cancer, a multicenter study. In Vivo. 201933(1)281 7. https://doi.Org/102l873/inviva.11473.

12 Bonotto M, Gerratana L, Di Maio M, De Angelis C, Gnausero M, Moroso S, et al. Chemotherapy versus endocrine therapy as first-line treatment in patients with luminal-like HER2-negatlve metastatic breast cancer: a propensity score analysis. Breast. 2017;31:114-20. httpx//doi.org/l0.l016/j. breast2016.l0.021.

13. Xie J, Hao Y, Li N, Lin PL, Ohashi E, Koo V, et aL Clinical outcomes among HR+/HER2- metastatic breast cancer patients with multiple metastatic sites: a chart review study in the US. Exp Hematol Oncol. 2015;4(l):3l. httpsy/doL org/10.1186/S40164-015-0023-0.

14. Rogoz B, Houze de I'Aulnoit A, Duhamel A Houz^ de I'Aulnoit D. Thirty-year trends of survival and time-varying effects of prognostic factors in patients with metastatic breast cancer-a single institution experience. Clin Breast Cancer. 2018,18(3)246 53. https://doi.org/10.1016/j.dbc^

15. TSUJI W, Teramukai S, Ueno M, Toi M. Inamoto T. Prognostic factors for survival after first recurrence in breast cancer a retrospective analysis of 252 recurrent cases at a single institution. Breast Cancer. 2014;21 (1 ):86-95. https://doi.Org/l 0.1007/sl 2282-012-0358-x.

16. Jung SY, Rosenzweig M, Sereika SM. Linkov F, Brufsky A, Weissfeld JL Factors associated with mortality after breast cancer metastasis. Cancer Causes Control. 2012,23(1):103 12. https//doi.org/10.1007/s 10552-011-9859-8.

17. Largillier R, Ferrero JM, Doyen J, Barriere J, Namer M, Mari V, et al. Prognostic factors in 1,038 women with metastatic breast cancer. Ann Oncol. 2008:19(12)2012-9. https://doi.org/l0.1093/annonc/mdn424.

18. Andre F, Sllmane K, Bachelot T, Dunant A, Namer M, Barrelier A et al. Breast cancer with synchronous metastases: trends in survival during a 14-year period. J Clin Oncol. 2004:22(16)3302 8. https//doi.org/10.1200/JC02004 08.095.

19 Watanabe J, Hayashi T, Tadokoro Y, Nishimura S, Takahashi K. Clinical pattern of primary systemic therapy and outcomes of estrogen receptor- positive, HER2 negative metastatic breast cancer: a review of a single institution. Breast Cancer Res Treat. 2017;166(3):911 7. https//doi.org/10.1 007/s 10549-017^1478-Z.

20. Llombart-Cussac A, Pivot X, Biganzoli L. Cortes-Funes H, Pritchard KI, Pierga JY, et al. A prognostic factor index for overall survival in patients receiving first-line chemotherapy for HER2-negative advanced breast cancer: an analysis of the ATHENA trial. Breast. 2014;23(5):656 62. https://doi.org/10.l01 6/j.breast2014.06.017.

21 Cazzaniga M, Pronzato P, Leto di Priolo SL, De Matteis A, Di Costanzo F, Passalacqua R, et al. Patterns of relapse and modalities of treatment of breast cancer: the IRIS' project, a multicenter observational study. Oncology. 200466(4)260-8. https//doiorg/l0.1159/000078325.

22 Kwast AB, Voogd AG Menke-Pluijmers MB, Linn SC, Sonke GS, Kiemeney LA, et al. Prognostic factors for survival in metastatic breast cancer by hormone receptor status. Breast Cancer Res Treat. 2014;145(2):5O3 11. https7/doi. org/10.1007/s10549-014-2964-0.

23. Giordano SH, Buzdar AU, Smith TL, Kau SW, Yang Y, Hortobagyi GN. Is breast cancer survival improving? Cancer. 2004; 100(1X44 52. http$7/doi. org/10.1002/cncr.l 1859.

24. Wyld L, Gutteridge E, Pinder 5E. James JJ, Chan SY, Cheung KL, et al. Prognostic factors for patients with hepatic metastases from breast cancer. Br J Cancer. 2003:89(2)284-90. https7/doi.org/l0.l03&/sj.bjc.6601038.

25 Harvey JM, Clark GM, Osborne CK, Allred IX. Estrogen receptor status by immunohistochemistry is superior to the ligand binding assay for predicting response to adjuvant endocrine therapy in breast cancer. J Clin Oncol. 1999:17(5):1474-81. https://doi.org/10.l20Q/XO. 1999.17.5.1474.

26. Regierer AG Wolters R, Ufen MP. Weigel A, Novopashenny I, Kohne CH, et al. An internally and externally validated prognostic score for metastatic breast cancer: analysis of 2269 patients. Ann Oncol. 201425(3)633 8. https://doi.org/10.1093/annonc/mdt5 39.

27. Newton PK. Mason J, Venkatappa N, Jochelson MS, Hurt B, Nieva J, et al. Spatiotemporal progression of metastatic breast cancer a Markov chain model highlighting rhe role of early metastatic sites. NPJ Breast Cancer. 2015:1 (1):15018. https://doi.Org/10.l 038/npjbcancer2015.18.

28. Onken JS, Fekonja LS. Wehowsky R, Hubertus V, Vajkoczy P. Metastatic dissemination patterns of different primary tumors to the spine and other bones. Clin Exp Metastasis. 2019. hups//doi.org/10.1007/s10585-019-09987- w.

29. Kennecke H, Yerushalmi R. Woods R, Cheang MC, Voduc D, Speers CH, et al. Metastatic behavior of breast cancer subtypes. J Clin Oncol. 2010:28(20): 3271 7. https7/doi.org/l0.1200/JC0.2009.25.9820.

30. Kast K, Link T, Friedrich K, Petzold A Niedostatek A, Schoffer O, et al. Impact of breast cancer subtypes and patterns of metastasis on outcome. Breast Cancer Res Treat. 2015:150(3)621-9. https//doi.org/l 0.1007/s 1054901 5-3341-1

31. Turner NG Finn RS, Martin M. Im SA DeMichele A. Ettl J, et al. Clinical considerations of the role of palbociclib in the management of advanced breast cancer patients with and without visceral metastases. Ann Oncol. 2018:29(3)^69-80. httpST7doi.org/10.1093/annonc/mdx797.

参考文献をもっと見る